#METABOLOMICS WORKBENCH zhaom_20220406_224130 DATATRACK_ID:3180 STUDY_ID:ST002126 ANALYSIS_ID:AN003479 VERSION 1 CREATED_ON 05-31-2022 #PROJECT PR:PROJECT_TITLE Amino acid catabolism in hematopoietic cells PR:PROJECT_SUMMARY Hematopoietic stem cells (HSCs) adapt their metabolism to maintenance and PR:PROJECT_SUMMARY proliferation, but the mechanism remains incompletely understood. Here, we have PR:PROJECT_SUMMARY investigated the total levels, uptake and catabolism of amino acid in PR:PROJECT_SUMMARY hematopoietic stem cells, hemopoietic progenitors, and differentiated PR:PROJECT_SUMMARY hematopoietic cells. We have also studied the catabolism of amino acid in PR:PROJECT_SUMMARY hematopoietic stem cells under different conditions, such as homeostasis and PR:PROJECT_SUMMARY proliferation and with drug treatment. Moreover, glycolytic metabolite, NAD+ PR:PROJECT_SUMMARY precursor nicotinamide riboside (NR), accelerated AA catabolism to activate GCN2 PR:PROJECT_SUMMARY and sustain long-term function of HSCs. Overall, our study uncovers the direct PR:PROJECT_SUMMARY links between metabolic alterations and translation control in HSCs during PR:PROJECT_SUMMARY homeostasis and proliferation. PR:INSTITUTE Sun Yat-sen University PR:LAST_NAME Zhao PR:FIRST_NAME Meng PR:ADDRESS Zhongshan 2nd Road PR:EMAIL zhaom38@mail.sysu.edu.cn PR:PHONE 18138799889 PR:DOI http://dx.doi.org/10.21228/M8GD8D #STUDY ST:STUDY_TITLE Amino acids and TCA substrates in hematopoietic cells (Part3) ST:STUDY_SUMMARY This study uses [13C,15N] labeled amino acids to study the amino acid ST:STUDY_SUMMARY consumption and their catabolism into tricarboxylic acid cycle substrates in ST:STUDY_SUMMARY hematopoietic stem cells, hemopoietic progenitors, and differentiated ST:STUDY_SUMMARY hematopoietic cells under different conditions, such as homeostasis and ST:STUDY_SUMMARY proliferation and with drug treatment. ST:INSTITUTE Sun Yat-sen University ST:LAST_NAME Zhao ST:FIRST_NAME Meng ST:ADDRESS Zhongshan 2nd Road ST:EMAIL zhaom38@mail.sysu.edu.cn ST:PHONE 18138799889 ST:SUBMIT_DATE 2022-04-06 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - HSC_5FU_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-fu-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-fu-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-fu-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_0h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-0h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_0h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-0h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_0h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-0h-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_12h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-12h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_12h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-12h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_12h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-12h-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_6h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-6h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_6h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-6h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_ND_6h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nd-6h-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-ct-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-ct-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). RAW_FILE_NAME=hsc-ct-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_NR_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-ct-nr-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_NR_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-ct-nr-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_Ctrl_NR_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-ct-nr-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-fu-nr-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-fu-nr-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). RAW_FILE_NAME=hsc-fu-nr-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_0h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-0h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_0h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-0h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_0h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-0h-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_12h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-12h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_12h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-12h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_12h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-12h-3.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_6h_1 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-6h-1.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_6h_2 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-6h-2.cdf SUBJECT_SAMPLE_FACTORS - HSC_5FU_NR_6h_3 Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). RAW_FILE_NAME=hsc-fu-nr-6h-3.cdf #COLLECTION CO:COLLECTION_SUMMARY 5×10^5 indicated cells were incubated with 100 µM stable [13C,15N] amino acids CO:COLLECTION_SUMMARY (MSK-A2-US-1.2, Cambridge Isotope Laboratories) for indicated time and CO:COLLECTION_SUMMARY centrifuged at 500 g for 5 min at 4 °C. The pelleted cells were extracted in CO:COLLECTION_SUMMARY 500 µl ice-cold Acetonitrile: Isopropyl Alcohol: water (3:3:2 v/v/v) and CO:COLLECTION_SUMMARY aliquoted as three technical replicates. The extracts were vortexed for 5 min at CO:COLLECTION_SUMMARY 4 °C and centrifuged at 14,000 g for 2 min at 4 °C. The supernatants were CO:COLLECTION_SUMMARY dried by vacuum spin for subsequent derivatization and stored at -20 ℃. CO:SAMPLE_TYPE Bone marrow #TREATMENT TR:TREATMENT_SUMMARY Germ-free C57BL/6J mice were intraperitoneally injected with 10 mg/kg 5FU TR:TREATMENT_SUMMARY (F6627-5G, Sigma-Aldrich) for 14 days, or fed with vehicle or NR (400 mg/kg per TR:TREATMENT_SUMMARY day) (1341-23-7, ziyi-reagent) for consecutive 8 weeks (long-term) or 1 week TR:TREATMENT_SUMMARY (short-term). Hematopoietic cells were stained and sorted from treated mice. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY To get the corresponding derivatives, the dried aliquots were incubated with 20 SP:SAMPLEPREP_SUMMARY µL 2% (w/v) methoxyamine hydrochloride (226904, Sigma-Aldrich) in pyridine for SP:SAMPLEPREP_SUMMARY 60 min at 37 °C, and silylated by 30 µL of SP:SAMPLEPREP_SUMMARY N-Methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide with 1% SP:SAMPLEPREP_SUMMARY tert-Butyldimethylchlorosilane (TBDMS, 18162-48-6, Regis Technologies) for 30 SP:SAMPLEPREP_SUMMARY min at 45 °C. The corresponding derivatives were analyzed by GC-MS using the SP:SAMPLEPREP_SUMMARY Trace 1310 gas chromatograph (Thermo Fisher) with the DB-35ms column (Agilent SP:SAMPLEPREP_SUMMARY Technologies) connected to the Q ExactiveTM GC OrbitrapTM GC-MS/MS system SP:SAMPLEPREP_SUMMARY (Thermo Fisher). #CHROMATOGRAPHY CH:INSTRUMENT_NAME TRACE 1310 CH:COLUMN_NAME DB-35ms CH:CHROMATOGRAPHY_TYPE GC #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME Thermo Q Exactive Orbitrap MS:INSTRUMENT_TYPE Orbitrap MS:MS_TYPE EI MS:MS_COMMENTS GC-MS data was acquired on Q-Exactive Orbitrap mass spectrometer (Thermo Fisher) MS:MS_COMMENTS coupled with Gas Chromatograph system TRACE 1310 (Thermo Fisher). MS:MS_COMMENTS Chromatographic separation was performed on a DB-35ms column module (30 m length MS:MS_COMMENTS x 0.25 mm internal diameter, Agilent Technologies). The column temperature was MS:MS_COMMENTS programmed with an initial temperature of 50 °C for 2 min, then ramped at MS:MS_COMMENTS 10°C/min to 325 °C, and maintained for 5 min. The mass range was set as 50-600 MS:MS_COMMENTS m/z, and the resolution was 60,000. The ion source temperature was 300°C with MS:MS_COMMENTS the transfer line temperature of 250°C, and the electron energy was 70 eV with MS:MS_COMMENTS EI source. MS:ION_MODE POSITIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS Peak Area MS_METABOLITE_DATA_START Samples HSC_5FU_1 HSC_5FU_2 HSC_5FU_3 HSC_5FU_ND_0h_1 HSC_5FU_ND_0h_2 HSC_5FU_ND_0h_3 HSC_5FU_ND_12h_1 HSC_5FU_ND_12h_2 HSC_5FU_ND_12h_3 HSC_5FU_ND_6h_1 HSC_5FU_ND_6h_2 HSC_5FU_ND_6h_3 HSC_Ctrl_1 HSC_Ctrl_2 HSC_Ctrl_3 HSC_Ctrl_NR_1 HSC_Ctrl_NR_2 HSC_Ctrl_NR_3 HSC_5FU_NR_1 HSC_5FU_NR_2 HSC_5FU_NR_3 HSC_5FU_NR_0h_1 HSC_5FU_NR_0h_2 HSC_5FU_NR_0h_3 HSC_5FU_NR_12h_1 HSC_5FU_NR_12h_2 HSC_5FU_NR_12h_3 HSC_5FU_NR_6h_1 HSC_5FU_NR_6h_2 HSC_5FU_NR_6h_3 Factors Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). [13C_ 15N]Alanine_ 2TBDMS 66700.0000 68400.0000 68400.0000 2910000.0000 2520000.0000 2940000.0000 778000.0000 884000.0000 863000.0000 1600000.0000 1400000.0000 1370000.0000 61300.0000 60400.0000 63200.0000 63000.0000 76000.0000 52000.0000 2530000.0000 3060000.0000 3720000.0000 136000.0000 132000.0000 215000.0000 768000.0000 771000.0000 616000.0000 [13C_ 15N]Aspartic acid_ 3TBDMS 96300.0000 113000.0000 128000.0000 623000.0000 656000.0000 633000.0000 312000.0000 322000.0000 305000.0000 397000.0000 421000.0000 412000.0000 78400.0000 86300.0000 71300.0000 52800.0000 112000.0000 80700.0000 528000.0000 618000.0000 607000.0000 102000.0000 89300.0000 91300.0000 238000.0000 202000.0000 184000.0000 [13C_ 15N]Glutamic acid_ 3TBDMS 74200.0000 71200.0000 73100.0000 512000.0000 527000.0000 567000.0000 215000.0000 206000.0000 194000.0000 352000.0000 345000.0000 394000.0000 32500.0000 31200.0000 35200.0000 73700.0000 58400.0000 67400.0000 537000.0000 584000.0000 574000.0000 35200.0000 41400.0000 35700.0000 183000.0000 156000.0000 204000.0000 [13C_ 15N]Glycine_ 2TBDMS 87200.0000 68500.0000 79900.0000 6870000.0000 7140000.0000 7580000.0000 4290000.0000 4030000.0000 3300000.0000 4960000.0000 4930000.0000 4500000.0000 53400.0000 53500.0000 66900.0000 83000.0000 82000.0000 52400.0000 7740000.0000 6570000.0000 7040000.0000 2430000.0000 2010000.0000 1050000.0000 3640000.0000 2790000.0000 3000000.0000 [13C_ 15N]Histidine_ 3TBDMS 54100.0000 48700.0000 45200.0000 459000.0000 450000.0000 432000.0000 126000.0000 135000.0000 108000.0000 297000.0000 248000.0000 220000.0000 42300.0000 39900.0000 38400.0000 46800.0000 41000.0000 47200.0000 468000.0000 410000.0000 472000.0000 20200.0000 25400.0000 30000.0000 77300.0000 83800.0000 85600.0000 [13C_ 15N]Isoleucine_ 2TBDMS 183000.0000 163000.0000 163000.0000 2770000.0000 2530000.0000 3030000.0000 1320000.0000 1140000.0000 1220000.0000 1850000.0000 1930000.0000 2070000.0000 146000.0000 122000.0000 130000.0000 253000.0000 112000.0000 90000.0000 2530000.0000 3120000.0000 2900000.0000 268000.0000 244000.0000 205000.0000 702000.0000 693000.0000 704000.0000 [13C_ 15N]Leucine_ 2TBDMS 183000.0000 213000.0000 203000.0000 2270000.0000 3080000.0000 2640000.0000 909000.0000 829000.0000 881000.0000 1640000.0000 1740000.0000 1830000.0000 133000.0000 154000.0000 117000.0000 288000.0000 143000.0000 127000.0000 2880000.0000 3430000.0000 3270000.0000 293000.0000 204000.0000 181000.0000 988000.0000 825000.0000 882000.0000 [13C_ 15N]Lysine_ 3TBDMS 74600.0000 84600.0000 78400.0000 1180000.0000 1290000.0000 1200000.0000 480000.0000 478000.0000 456000.0000 746000.0000 755000.0000 826000.0000 58400.0000 51200.0000 56300.0000 104000.0000 71000.0000 118000.0000 1040000.0000 1210000.0000 1180000.0000 42700.0000 31100.0000 50100.0000 258000.0000 297000.0000 284000.0000 [13C_ 15N]Methionine_ 2TBDMS 183000.0000 173000.0000 193000.0000 1520000.0000 1740000.0000 1670000.0000 454000.0000 454000.0000 606000.0000 917000.0000 845000.0000 912000.0000 152000.0000 130000.0000 142000.0000 192000.0000 143000.0000 142000.0000 1620000.0000 1430000.0000 1420000.0000 85700.0000 87600.0000 90400.0000 465000.0000 518000.0000 324000.0000 [13C_ 15N]Phenylalanine_ 2TBDMS 132000.0000 142000.0000 125000.0000 2050000.0000 2040000.0000 2430000.0000 990000.0000 938000.0000 1140000.0000 1330000.0000 1200000.0000 1220000.0000 115000.0000 105000.0000 125000.0000 110000.0000 175000.0000 146000.0000 2000000.0000 2750000.0000 2460000.0000 226000.0000 237000.0000 283000.0000 602000.0000 426000.0000 702000.0000 [13C_ 15N]Proline_ 2TBDMS 143000.0000 132000.0000 133000.0000 1630000.0000 1540000.0000 1480000.0000 489000.0000 402000.0000 437000.0000 759000.0000 758000.0000 707000.0000 78500.0000 86300.0000 88500.0000 143000.0000 175000.0000 152000.0000 1430000.0000 1750000.0000 1520000.0000 125000.0000 96000.0000 113000.0000 406000.0000 381000.0000 401000.0000 [13C_ 15N]Serine_ 3TBDMS 132000.0000 125000.0000 130000.0000 2860000.0000 3140000.0000 3060000.0000 783000.0000 821000.0000 841000.0000 2100000.0000 1940000.0000 2040000.0000 84200.0000 75100.0000 80100.0000 199000.0000 116000.0000 182000.0000 2990000.0000 3160000.0000 2820000.0000 187000.0000 149000.0000 135000.0000 806000.0000 715000.0000 812000.0000 [13C_ 15N]Threonine_ 3TBDMS 17500.0000 18700.0000 20000.0000 684000.0000 702000.0000 678000.0000 283000.0000 299000.0000 253000.0000 412000.0000 388000.0000 396000.0000 12500.0000 14300.0000 14400.0000 19000.0000 26200.0000 20700.0000 690000.0000 662000.0000 707000.0000 86300.0000 75600.0000 74200.0000 252000.0000 210000.0000 223000.0000 [13C_ 15N]Tyrosine_ 3TBDMS 855000.0000 812000.0000 832000.0000 6730000.0000 6950000.0000 6630000.0000 1500000.0000 1720000.0000 1780000.0000 3560000.0000 3050000.0000 2620000.0000 523000.0000 488000.0000 512000.0000 762000.0000 836000.0000 916000.0000 5620000.0000 6360000.0000 7160000.0000 401000.0000 309000.0000 455000.0000 1510000.0000 1680000.0000 1470000.0000 [13C_ 15N]Valine_ 2TBDMS 63200.0000 61300.0000 64300.0000 7380000.0000 6020000.0000 6730000.0000 2510000.0000 2600000.0000 3340000.0000 4620000.0000 4660000.0000 3680000.0000 41200.0000 43200.0000 41300.0000 58000.0000 45000.0000 86000.0000 6580000.0000 7050000.0000 7560000.0000 804000.0000 821000.0000 733000.0000 2170000.0000 1650000.0000 2510000.0000 [13C]Alpha_Ketoglutarate 6380000.0000 6250000.0000 6110000.0000 5130.0000 4850.0000 4760.0000 7580.0000 7260.0000 7370.0000 6030.0000 6430.0000 6900.0000 4010000.0000 4120000.0000 4180000.0000 6240.0000 7240.0000 6930.0000 19500.0000 17300.0000 21600.0000 9690.0000 9530.0000 11500.0000 [13C]Citrate 14400000.0000 14200000.0000 15200000.0000 77000.0000 79500.0000 77000.0000 101000.0000 93000.0000 103000.0000 83700.0000 81100.0000 89300.0000 8530000.0000 7950000.0000 7680000.0000 135000.0000 145000.0000 144000.0000 261000.0000 258000.0000 263000.0000 202000.0000 216000.0000 188000.0000 [13C]Fumatate 62200000.0000 62300000.0000 62300000.0000 90800.0000 98000.0000 93200.0000 120000.0000 113000.0000 125000.0000 119000.0000 119000.0000 116000.0000 41100000.0000 40100000.0000 42000000.0000 139000.0000 145000.0000 147000.0000 345000.0000 340000.0000 348000.0000 256000.0000 235000.0000 261000.0000 [13C]Malate 21600000.0000 24000000.0000 22900000.0000 9790.0000 12700.0000 13200.0000 14800.0000 13200.0000 14000.0000 12400.0000 12800.0000 13400.0000 11700000.0000 9260000.0000 10400000.0000 26000.0000 27200.0000 26800.0000 41300.0000 46000.0000 42700.0000 32400.0000 32200.0000 29300.0000 [13C]Succinate 67300000.0000 61300000.0000 65300000.0000 31700.0000 34400.0000 32100.0000 50400.0000 53200.0000 50700.0000 47700.0000 41600.0000 47500.0000 41700000.0000 40900000.0000 42900000.0000 49100.0000 45300.0000 51300.0000 113000.0000 112000.0000 134000.0000 75700.0000 77300.0000 73100.0000 Alanine_ 2TBDMS 5200000.0000 4720000.0000 5210000.0000 1230000.0000 1590000.0000 1420000.0000 829000.0000 856000.0000 973000.0000 2170000.0000 2150000.0000 2060000.0000 Alpha_Ketoglutarate 6380000.0000 6250000.0000 6110000.0000 4010000.0000 4120000.0000 4180000.0000 3420000.0000 2900000.0000 3710000.0000 3810000.0000 3730000.0000 4070000.0000 Aspartic acid_ 3TBDMS 154000000.0000 135000000.0000 137000000.0000 42100000.0000 45200000.0000 47600000.0000 19000000.0000 19500000.0000 24200000.0000 37400000.0000 30800000.0000 42300000.0000 Citrate 14400000.0000 14200000.0000 15200000.0000 8530000.0000 7950000.0000 7680000.0000 1620000.0000 1360000.0000 1440000.0000 4160000.0000 3990000.0000 3980000.0000 Fumatate 62200000.0000 62300000.0000 62300000.0000 41100000.0000 40100000.0000 42000000.0000 33400000.0000 36900000.0000 33500000.0000 38300000.0000 41300000.0000 41900000.0000 Glutamic acid_ 3TBDMS 132000000.0000 142000000.0000 174000000.0000 42100000.0000 40300000.0000 43600000.0000 13600000.0000 13900000.0000 17800000.0000 42600000.0000 42600000.0000 39900000.0000 Glutamine_ 3TBDMS 1740000.0000 1860000.0000 1520000.0000 386000.0000 412000.0000 432000.0000 238000.0000 279000.0000 202000.0000 582000.0000 469000.0000 483000.0000 Glycine_ 2TBDMS 542000000.0000 612000000.0000 586000000.0000 253000000.0000 214000000.0000 253000000.0000 106000000.0000 82400000.0000 106000000.0000 126000000.0000 157000000.0000 139000000.0000 Histidine_ 3TBDMS 284000.0000 320000.0000 218000.0000 52100.0000 41900.0000 52900.0000 24300.0000 24100.0000 29700.0000 37900.0000 40300.0000 39600.0000 Hydroxyproline_ (E)-_ 3TBDMS 4760000.0000 5200000.0000 5340000.0000 1190000.0000 1390000.0000 1240000.0000 805000.0000 702000.0000 639000.0000 1580000.0000 1460000.0000 1570000.0000 Isoleucine_ 2TBDMS 15400000.0000 17400000.0000 18400000.0000 5410000.0000 5120000.0000 5340000.0000 2420000.0000 2500000.0000 3240000.0000 3660000.0000 4910000.0000 4820000.0000 L-Cysteine_ 3TBDMS 3250000.0000 2840000.0000 3100000.0000 686000.0000 854000.0000 774000.0000 32500.0000 31800.0000 35500.0000 65000.0000 68600.0000 76500.0000 Leucine_ 2TBDMS 41900000.0000 45800000.0000 43900000.0000 12000000.0000 13900000.0000 14100000.0000 4780000.0000 5000000.0000 6230000.0000 7030000.0000 9670000.0000 11700000.0000 Lysine_ 3TBDMS 15200000.0000 18600000.0000 14400000.0000 4220000.0000 3420000.0000 4180000.0000 2220000.0000 2110000.0000 2810000.0000 4750000.0000 4090000.0000 3970000.0000 Malate 21600000.0000 24000000.0000 22900000.0000 11700000.0000 9260000.0000 10400000.0000 8150000.0000 8380000.0000 7100000.0000 10100000.0000 11800000.0000 11000000.0000 Methionine_ 2TBDMS 12300000.0000 14200000.0000 13400000.0000 3520000.0000 3100000.0000 3370000.0000 1040000.0000 1040000.0000 1210000.0000 2580000.0000 2840000.0000 2220000.0000 Phenylalanine_ 2TBDMS 6520000.0000 4320000.0000 6320000.0000 1860000.0000 2100000.0000 2100000.0000 1210000.0000 1230000.0000 1590000.0000 2770000.0000 2070000.0000 2330000.0000 Proline_ 2TBDMS 65500000.0000 58200000.0000 87000000.0000 10200000.0000 13200000.0000 12500000.0000 5270000.0000 5160000.0000 7120000.0000 18400000.0000 18700000.0000 16200000.0000 Serine_ 3TBDMS 52200000.0000 51700000.0000 56000000.0000 18600000.0000 21800000.0000 20900000.0000 7280000.0000 6280000.0000 8750000.0000 14400000.0000 16500000.0000 17900000.0000 Succinate 67300000.0000 61300000.0000 65300000.0000 41700000.0000 40900000.0000 42900000.0000 31900000.0000 36600000.0000 31700000.0000 35300000.0000 36600000.0000 39800000.0000 Threonine_ 3TBDMS 8540000.0000 7420000.0000 6230000.0000 2860000.0000 2510000.0000 2150000.0000 1150000.0000 985000.0000 1600000.0000 2380000.0000 2430000.0000 2190000.0000 Tyrosine_ 3TBDMS 18400000.0000 21600000.0000 21000000.0000 4720000.0000 5820000.0000 6340000.0000 2760000.0000 3000000.0000 3840000.0000 4340000.0000 6530000.0000 6240000.0000 Valine_ 2TBDMS 52100000.0000 42300000.0000 51200000.0000 11200000.0000 13200000.0000 14200000.0000 5170000.0000 5230000.0000 6950000.0000 8890000.0000 11200000.0000 15900000.0000 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name pubchem_id inchi_key kegg_id other_id other_id_type ri ri_type moverz_quant [13C, 15N]Alanine, 2TBDMS 15.06 [13C, 15N]Aspartic acid, 3TBDMS 21.49 [13C, 15N]Glutamic acid, 3TBDMS 22.54 [13C, 15N]Glycine, 2TBDMS 15.39 [13C, 15N]Histidine, 3TBDMS 25.11 [13C, 15N]Isoleucine, 2TBDMS 17.26 [13C, 15N]Leucine, 2TBDMS 16.91 [13C, 15N]Lysine, 3TBDMS 23.48 [13C, 15N]Methionine, 2TBDMS 19.74 [13C, 15N]Phenylalanine, 2TBDMS 20.92 [13C, 15N]Proline, 2TBDMS 20.49 [13C, 15N]Serine, 3TBDMS 19.94 [13C, 15N]Threonine, 3TBDMS 20.22 [13C, 15N]Tyrosine, 3TBDMS 25.51 [13C, 15N]Valine, 2TBDMS 16.46 [13C]Alpha_Ketoglutarate 21.03 [13C]Citrate 26.51 [13C]Fumatate 18.77 [13C]Malate 22.05 [13C]Succinate 18.37 Alanine, 2TBDMS 15.06 Alpha_Ketoglutarate 21.02 Aspartic acid, 3TBDMS 21.48 Citrate 26.51 Fumatate 18.76 Glutamic acid, 3TBDMS 22.53 Glutamine, 3TBDMS 23.81 Glycine, 2TBDMS 15.38 Histidine, 3TBDMS 25.10 Hydroxyproline, (E)-, 3TBDMS 21.77 Isoleucine, 2TBDMS 17.25 L-Cysteine, 3TBDMS 21.94 Leucine, 2TBDMS 16.90 Lysine, 3TBDMS 23.47 Malate 22.04 Methionine, 2TBDMS 19.73 Phenylalanine, 2TBDMS 20.91 Proline, 2TBDMS 20.48 Serine, 3TBDMS 19.93 Succinate 18.37 Threonine, 3TBDMS 20.21 Tyrosine, 3TBDMS 25.50 Valine, 2TBDMS 16.45 METABOLITES_END #END